Modular Approaches to Understand the Immunobiology of Human Immunodeficiency Virus Latency

2021 ◽  
Author(s):  
Gideon Wolf ◽  
Nevil J. Singh
2016 ◽  
Vol 3 (4) ◽  
Author(s):  
Héloïse M. Delagrèverie ◽  
Constance Delaugerre ◽  
Sharon R. Lewin ◽  
Steven G. Deeks ◽  
Jonathan Z. Li

Abstract In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies include latency reversal agents (LRAs) designed to reactivate HIV-1 ribonucleic acid transcription and virus production and a variety of immune-modifying drugs designed to reverse latency, block homeostatic proliferation, and replenish the viral reservoir, eliminate virus-producing cells, and/or control HIV replication after cessation of antiretroviral therapy. This review provides a summary of ongoing clinical trials of HIV LRAs and immunomodulatory molecules, and it highlights challenges in the comparison and interpretation of the expected trial results.


Retrovirology ◽  
2014 ◽  
Vol 11 (1) ◽  
Author(s):  
Paresh Patel ◽  
Mohammad Yunus Ansari ◽  
Shraddha Bapat ◽  
Madhuri Thakar ◽  
Raman Gangakhedkar ◽  
...  

1987 ◽  
Vol 1 (3) ◽  
pp. 381-395 ◽  
Author(s):  
Beverly Ryan ◽  
Edward Connor ◽  
Anthony Minnefor ◽  
Frank Desposito ◽  
James Oleske

2001 ◽  
Vol 36 (3) ◽  
pp. 225-234
Author(s):  
Ramazan Idilman ◽  
Alessandra Colantoni ◽  
Nicola De Maria ◽  
James M. Harig ◽  
David H. van Thiel

Sign in / Sign up

Export Citation Format

Share Document